Kulovac Benjamin, Aganović Damir, Prcić Alden, Hadziosmanović Osman
Urology Clinic, University of Sarajevo Clinics Centre, Bolnicka 25, 71 000 Sarajevo, Bosnia and Herzegovina.
Bosn J Basic Med Sci. 2007 Aug;7(3):245-9. doi: 10.17305/bjbms.2007.3053.
Chronic nonbacterial prostatitis/chronic pelvic pain syndrome is unsatisfactorily defined and insufficiently studied illness. Also, the treatment success is questionable and therefore, this illness is a therapeutical problem for urologists--which medications are the best choice in treating this uncomfortable condition? This paper presents results of prospective, open, analytical, comparative study that was performed on 90 patients with diagnosed chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Patients were divided into three groups and were treated with two medications ciprofloxacin (C), doxazosin (D) and combination of ciprofloxacin + doxazosin (C+D). The effects were measured using symptom questionnaire for prostate illnesses of the National Institute for Health - USA (NIH-CPSI). During the basic evaluation, sum ranging from 0 to 43 was calculated for each patient. This number is called total sum NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) of the questionnaire, which generates the questions from 1 to 9. The most significant change occurred in C+D group where the total sum changed from 18-38 in the beginning to 5-31 at the end of the treatment (55,1% (p<0,001)). Significant changes were also found in D group where the change was 46, 4% (p<0,001). At the end of the treatment no significant change was registered in C group (p<0,005): p<0,001--significance threshold. Combination of ciprofloxacin + doxazosin proved to be the best choice for treatment.
慢性非细菌性前列腺炎/慢性盆腔疼痛综合征是一种定义不明确且研究不足的疾病。此外,治疗效果存在疑问,因此,这种疾病对泌尿科医生来说是一个治疗难题——哪种药物是治疗这种不适状况的最佳选择?本文介绍了一项针对90例诊断为慢性非细菌性前列腺炎/慢性盆腔疼痛综合征患者进行的前瞻性、开放性、分析性、对比性研究的结果。患者被分为三组,分别接受两种药物治疗,即环丙沙星(C)、多沙唑嗪(D)以及环丙沙星+多沙唑嗪联合用药(C+D)。使用美国国立卫生研究院的前列腺疾病症状问卷(NIH-CPSI)来衡量治疗效果。在基础评估期间,为每位患者计算了0至43的总和。这个数字被称为问卷的NIH-CPSI总分(美国国立卫生研究院慢性前列腺炎症状指数),该问卷包含1至9个问题。C+D组出现了最显著的变化,治疗开始时总分在18至38之间,治疗结束时变为5至31(55.1%,p<0.001)。D组也发现了显著变化,变化率为46.4%(p<0.001)。治疗结束时,C组未出现显著变化(p<0.005):p<0.001为显著性阈值。环丙沙星+多沙唑嗪联合用药被证明是治疗的最佳选择。